New therapeutic patents used for the treatment of leprosy: a review.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Cambridge University Press Country of Publication: England NLM ID: 8703737 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1469-4409 (Electronic) Linking ISSN: 09502688 NLM ISO Abbreviation: Epidemiol Infect Subsets: MEDLINE
    • Publication Information:
      Original Publication: Cambridge Eng : Cambridge University Press
    • Subject Terms:
      Drug Development* ; Patents as Topic*; Leprosy/*drug therapy; Anti-Bacterial Agents/therapeutic use ; Antibodies/therapeutic use ; Humans ; Peptides/therapeutic use ; Synthetic Drugs/therapeutic use
    • Abstract:
      Leprosy is a granulomatous disease, infectious and transmissible, which affects the skin and peripheral nerves, having Mycobacterium leprae as causative agent. The manifestation of this disease causes cutaneous lesions, peripheral neuropathies and, in more extreme cases, may generate deformities and disabilities in affected individuals. Patents were identified using the descriptor 'leprosy' and code A61K of the international patent classification, which indicates only products that meet human needs. The analysis was made using the WIPO, ESPACENET and USPTO databases, until the month of September 2016. Through this review, we found a variety of in vitro, pre-clinical and clinical studies relating to the treatment of leprosy with different types of compounds and forms of administration. New treatment proposals should include pain reduction capabilities, prevention or limitation of the appearance of cutaneous lesions, as well as prevention of the progression of the disease to more severe stages that may lead to loss of function or potentiate the individual's immune response to the M. leprae bacillus in order to prevent bacterial spread. We concluded that any patents developed with natural products were not found in the treatment of leprosy. All the deposited products were synthetic origin, mostly tested in humans and of varied forms of administration.
    • References:
      Blood. 2009 Feb 12;113(7):1399-407. (PMID: 18757776)
      Microb Pathog. 2017 Mar;104:116-124. (PMID: 28088473)
      Infect Immun. 2010 Nov;78(11):4634-43. (PMID: 20713631)
      Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255-73. (PMID: 5950347)
      Front Immunol. 2017 Mar 13;8:233. (PMID: 28348555)
      Nature. 2013 Jan 17;493(7432):346-55. (PMID: 23325217)
      Food Chem Toxicol. 2008 Feb;46(2):446-75. (PMID: 17996351)
      Lepr Rev. 2004 Mar;75(1):7-18. (PMID: 15072122)
      Int J Rheum Dis. 2016 Oct;19(10):1024-1031. (PMID: 26250118)
      PLoS Negl Trop Dis. 2015 Sep 09;9(9):e0004065. (PMID: 26351858)
    • Contributed Indexing:
      Keywords: Hansen's disease; Mycobacterium leprae; leprosy; therapeutic compositions; treatment for leprosy
    • Accession Number:
      0 (Anti-Bacterial Agents)
      0 (Antibodies)
      0 (Peptides)
      0 (Synthetic Drugs)
    • Publication Date:
      Date Created: 20180808 Date Completed: 20190503 Latest Revision: 20240904
    • Publication Date:
      20240904
    • Accession Number:
      PMC9506703
    • Accession Number:
      10.1017/S0950268818002145
    • Accession Number:
      30081970